U.S. flag

An official website of the United States government

NM_000546.6(TP53):c.440T>A (p.Val147Asp) AND Li-Fraumeni syndrome

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jul 3, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002051460.7

Allele description [Variation Report for NM_000546.6(TP53):c.440T>A (p.Val147Asp)]

NM_000546.6(TP53):c.440T>A (p.Val147Asp)

Gene:
TP53:tumor protein p53 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17p13.1
Genomic location:
Preferred name:
NM_000546.6(TP53):c.440T>A (p.Val147Asp)
HGVS:
  • NC_000017.11:g.7675172A>T
  • NG_017013.2:g.17379T>A
  • NM_000546.6:c.440T>AMANE SELECT
  • NM_001126112.3:c.440T>A
  • NM_001126113.3:c.440T>A
  • NM_001126114.3:c.440T>A
  • NM_001126115.2:c.44T>A
  • NM_001126116.2:c.44T>A
  • NM_001126117.2:c.44T>A
  • NM_001126118.2:c.323T>A
  • NM_001276695.3:c.323T>A
  • NM_001276696.3:c.323T>A
  • NM_001276697.3:c.-38T>A
  • NM_001276698.3:c.-38T>A
  • NM_001276699.3:c.-38T>A
  • NM_001276760.3:c.323T>A
  • NM_001276761.3:c.323T>A
  • NP_000537.3:p.Val147Asp
  • NP_001119584.1:p.Val147Asp
  • NP_001119585.1:p.Val147Asp
  • NP_001119586.1:p.Val147Asp
  • NP_001119587.1:p.Val15Asp
  • NP_001119588.1:p.Val15Asp
  • NP_001119589.1:p.Val15Asp
  • NP_001119590.1:p.Val108Asp
  • NP_001263624.1:p.Val108Asp
  • NP_001263625.1:p.Val108Asp
  • NP_001263689.1:p.Val108Asp
  • NP_001263690.1:p.Val108Asp
  • LRG_321:g.17379T>A
  • NC_000017.10:g.7578490A>T
Protein change:
V108D
Links:
dbSNP: rs1453167097
NCBI 1000 Genomes Browser:
rs1453167097
Molecular consequence:
  • NM_001276697.3:c.-38T>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001276698.3:c.-38T>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001276699.3:c.-38T>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_000546.6:c.440T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126112.3:c.440T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126113.3:c.440T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126114.3:c.440T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126115.2:c.44T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126116.2:c.44T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126117.2:c.44T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126118.2:c.323T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276695.3:c.323T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276696.3:c.323T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276760.3:c.323T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276761.3:c.323T>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Li-Fraumeni syndrome (LFS)
Synonyms:
Sarcoma family syndrome of Li and Fraumeni
Identifiers:
MONDO: MONDO:0018875; MedGen: C0085390; OMIM: PS151623

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002114385Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Jul 3, 2021)
germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9. Epub 2003 Jun 25.

PubMed [citation]
PMID:
12826609
PMCID:
PMC166245

A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation.

Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A, Hopf TA, Marks DS, Oren M, Segal E.

Mol Cell. 2018 Jul 5;71(1):178-190.e8. doi: 10.1016/j.molcel.2018.06.012. Erratum in: Mol Cell. 2018 Sep 6;71(5):873. doi: 10.1016/j.molcel.2018.08.013..

PubMed [citation]
PMID:
29979965
See all PubMed Citations (4)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV002114385.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this variant affects TP53 protein function (PMID: 12826609, 29979965, 30224644). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TP53 protein function. This variant has been observed in individual(s) with clinical features of Li-Fraumeni syndrome (Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change replaces valine with aspartic acid at codon 147 of the TP53 protein (p.Val147Asp). The valine residue is highly conserved and there is a large physicochemical difference between valine and aspartic acid.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 16, 2025